171 related articles for article (PubMed ID: 20541653)
1. Non FDG PET.
Nanni C; Fantini L; Nicolini S; Fanti S
Clin Radiol; 2010 Jul; 65(7):536-48. PubMed ID: 20541653
[TBL] [Abstract][Full Text] [Related]
2. Non-FDG PET in the practice of oncology.
Caroli P; Nanni C; Rubello D; Alavi A; Fanti S
Indian J Cancer; 2010; 47(2):120-5. PubMed ID: 20448372
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of oncological [11C]radiopharmaceuticals for clinical PET.
Lodi F; Malizia C; Castellucci P; Cicoria G; Fanti S; Boschi S
Nucl Med Biol; 2012 May; 39(4):447-60. PubMed ID: 22172394
[TBL] [Abstract][Full Text] [Related]
4. [Tracers in oncology - preclinical and clinical evaluation].
Krause BJ; Schwarzenböck S; Schwaiger M
Nuklearmedizin; 2010; 49 Suppl 1():S41-5. PubMed ID: 21152689
[TBL] [Abstract][Full Text] [Related]
5. PET and PET-CT. State of the art and future prospects.
Fanti S; Franchi R; Battista G; Monetti N; Canini R
Radiol Med; 2005; 110(1-2):1-15. PubMed ID: 16163136
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of positron emission tomographic tracers for imaging of papillomavirus-induced tumors in rabbits.
Probst S; Wiehr S; Mantlik F; Schmidt H; Kolb A; Münch P; Delcuratolo M; Stubenrauch F; Pichler BJ; Iftner T
Mol Imaging; 2014; 13():. PubMed ID: 24622808
[TBL] [Abstract][Full Text] [Related]
7. The role of new PET tracers for lung cancer.
Szyszko TA; Yip C; Szlosarek P; Goh V; Cook GJ
Lung Cancer; 2016 Apr; 94():7-14. PubMed ID: 26973200
[TBL] [Abstract][Full Text] [Related]
8. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
9. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
[TBL] [Abstract][Full Text] [Related]
10. Comparison of sigma-ligands and metabolic PET tracers for differentiating tumor from inflammation.
van Waarde A; Jager PL; Ishiwata K; Dierckx RA; Elsinga PH
J Nucl Med; 2006 Jan; 47(1):150-4. PubMed ID: 16391199
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
[TBL] [Abstract][Full Text] [Related]
12. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
13. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.
Hara T; Bansal A; DeGrado TR
Nucl Med Biol; 2006 Nov; 33(8):977-84. PubMed ID: 17127170
[TBL] [Abstract][Full Text] [Related]
14. PET tracers in musculoskeletal disease beyond FDG.
Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
[TBL] [Abstract][Full Text] [Related]
15. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging and targeted therapies in oncology: new concepts in treatment response assessment. a collection of cases.
Pantaleo MA; Nannini M; Lopci E; Castellucci P; Maleddu A; Lodi F; Nanni C; Allegri V; Astorino M; Brandi G; Di Battista M; Boschi S; Fanti S; Biasco G
Int J Oncol; 2008 Sep; 33(3):443-52. PubMed ID: 18695872
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography for radiation treatment planning.
Grosu AL; Piert M; Weber WA; Jeremic B; Picchio M; Schratzenstaller U; Zimmermann FB; Schwaiger M; Molls M
Strahlenther Onkol; 2005 Aug; 181(8):483-99. PubMed ID: 16044216
[TBL] [Abstract][Full Text] [Related]
18. Early response of sigma-receptor ligands and metabolic PET tracers to 3 forms of chemotherapy: an in vitro study in glioma cells.
van Waarde A; Been LB; Ishiwata K; Dierckx RA; Elsinga PH
J Nucl Med; 2006 Sep; 47(9):1538-45. PubMed ID: 16954564
[TBL] [Abstract][Full Text] [Related]
19. [The use of 18F-fluorothymidine and 18F-fluorocholine in imaging with positron emission tomography].
Skoura E; Datseris IE
Hell J Nucl Med; 2010; 13(1):88-90. PubMed ID: 20411184
[TBL] [Abstract][Full Text] [Related]
20. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]